Gemina Laboratories (GLAB) Stock Overview
A biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GLAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.47 |
| 52 Week High | CA$1.25 |
| 52 Week Low | CA$0.30 |
| Beta | 0.22 |
| 1 Month Change | -6.00% |
| 3 Month Change | -11.32% |
| 1 Year Change | 42.42% |
| 3 Year Change | 4.44% |
| 5 Year Change | n/a |
| Change since IPO | 10.59% |
Recent News & Updates
Shareholder Returns
| GLAB | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 4.4% | -1.4% | 0.4% |
| 1Y | 42.4% | -6.3% | 19.5% |
Return vs Industry: GLAB exceeded the Canadian Biotechs industry which returned -6.3% over the past year.
Return vs Market: GLAB exceeded the Canadian Market which returned 19.5% over the past year.
Price Volatility
| GLAB volatility | |
|---|---|
| GLAB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 20.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: GLAB's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine GLAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis.
Gemina Laboratories Ltd. Fundamentals Summary
| GLAB fundamental statistics | |
|---|---|
| Market cap | CA$35.99m |
| Earnings (TTM) | -CA$4.01m |
| Revenue (TTM) | CA$10.88k |
Is GLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAB income statement (TTM) | |
|---|---|
| Revenue | CA$10.88k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$10.88k |
| Other Expenses | CA$4.02m |
| Earnings | -CA$4.01m |
Last Reported Earnings
Apr 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 100.00% |
| Net Profit Margin | -36,856.52% |
| Debt/Equity Ratio | -5.5% |
How did GLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 06:02 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/04/30 |
| Annual Earnings | 2025/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gemina Laboratories Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.